We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Sociedad Química y Minera de Chile
SQM
$19.3B
| $10.6M | 0.02% |
153,606
-27,152
| -15% | -$1.5M |
|
602
Acadia Healthcare
ACHC
$2.55B
| $10.6M | 0.02% |
743,925
+312,172
| +72% | +$5.91M |
|
603
Check Point Software Technologies
CHKP
$14.3B
| $10.5M | 0.02% |
56,835
-384
| -0.7% | -$74.2K |
|
604
Zebra Technologies
ZBRA
$13.5B
| $10.5M | 0.02% |
43,221
+1,400
| +3% | +$374K |
|
605
BJs Wholesale Club
BJ
$12.8B
| $10.5M | 0.02% |
116,405
-91,512
| -44% | -$8.4M |
|
606
Carlyle Group
CG
$16.1B
| $10.4M | 0.02% |
175,708
-7,502
| -4% | -$426K |
|
|
CNH
607
CNH Industrial
CNH
$13.3B
| $10.4M | 0.02% |
1,124,443
-3,218
| -0.3% | -$32.1K |
|
608
Pinterest
PINS
$13.7B
| $10.3M | 0.02% |
399,478
-1,089
| -0.3% | -$31.4K |
|
609
Fox Class A
FOXA
$24.8B
| $10.3M | 0.02% |
141,518
-12,895
| -8% | -$843K |
|
610
Okta
OKTA
$23.8B
| $10.3M | 0.02% |
118,681
+5,362
| +5% | +$468K |
|
611
Jazz Pharmaceuticals
JAZZ
$16.1B
| $10.3M | 0.02% |
60,337
-5,133
| -8% | -$787K |
|
612
F5
FFIV
$22B
| $10.3M | 0.02% |
40,169
+8,280
| +26% | +$2.23M |
|
613
Genuine Parts
GPC
$17.9B
| $10.2M | 0.02% |
82,652
-3,430
| -4% | -$444K |
|
614
Avery Dennison
AVY
$12.8B
| $9.82M | 0.02% |
53,967
-3,274
| -6% | -$566K |
|
615
Twist Bioscience
TWST
$5.32B
| $9.77M | 0.02% |
308,116
-12,167
| -4% | -$380K |
|
616
Krystal Biotech
KRYS
$10.7B
| $9.7M | 0.02% |
39,360
-20,012
| -34% | -$4.21M |
|
617
Roblox
RBLX
$35.9B
| $9.56M | 0.01% |
117,928
+1,887
| +2% | +$200K |
|
618
GoDaddy
GDDY
$13.9B
| $9.52M | 0.01% |
76,715
-7,890
| -9% | -$1.02M |
|
619
Aaon
AAON
$6.95B
| $9.51M | 0.01% |
124,672
-924
| -0.7% | -$85.3K |
|
|
CTRA
620
DELISTED
Coterra Energy
CTRA
| $9.5M | 0.01% |
361,106
-46,005
| -11% | -$1.16M |
|
621
Laureate Education
LAUR
$5.38B
| $9.44M | 0.01% |
280,389
+19,120
| +7% | +$590K |
|
622
Dow Inc
DOW
$22B
| $9.43M | 0.01% |
403,279
-82
| -0% | -$1.89K |
|
623
Arcus Biosciences
RCUS
$3.33B
| $9.17M | 0.01% |
384,601
+52,930
| +16% | +$1.08M |
|
624
Autohome
ATHM
$2.62B
| $9.12M | 0.01% |
409,689
+24,338
| +6% | +$609K |
|
|
CPRX
625
DELISTED
Catalyst Pharmaceutical
CPRX
| $9.05M | 0.01% |
387,910
-244,531
| -39% | -$5.45M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.